A common blood-pressure drug is tied to a third higher risk of serious kidney damage in diabetics

A widely prescribed class of blood-pressure medication has been linked to a meaningfully higher risk of serious kidney decline in people with type 2 diabetes, even among patients already taking newer drugs designed to protect the kidneys. The finding, presented by researchers at a major kidney congress, is prompting questions about whether these medications are always the safest second choice for patients with diabetic kidney disease. Because the analysis was observational, its authors stress that it points to an association rather than a proven cause.

A study tracking more than 31,000 diabetes patients

The research examined health data from 31,031 adults with type 2 diabetes treated between 2016 and 2021. Every participant was already receiving two classes of medication now considered standard for protecting kidney function: renin-angiotensin system inhibitors, which lower blood pressure and reduce pressure inside the kidney’s filtering units, and sodium-glucose cotransporter-2 inhibitors, originally developed for diabetes but now recognized for their ability to guard the kidneys. Within that group, 12,172 patients, about 39 percent, were also taking the drug class under scrutiny, while roughly 60 percent were treated with other blood-pressure medications. The median follow-up period was approximately 3.5 years, according to findings summarized by the European Renal Association.

The drugs in question: dihydropyridine calcium-channel blockers

The medications at the center of the study are dihydropyridine calcium-channel blockers, a common group of blood-pressure drugs that work by relaxing blood vessels. They are frequently prescribed as second-line treatments for people with diabetic kidney disease when additional blood-pressure control is needed. Familiar members of this class include amlodipine, one of the most commonly dispensed blood-pressure medications, which is described in consumer drug references maintained by the U.S. National Library of Medicine through its MedlinePlus resource. Their widespread use is part of why the new signal has drawn attention, since even a modest increase in risk could affect a large number of patients.

A 33 percent higher risk of major kidney events

After adjusting for differences in patients’ baseline clinical and demographic characteristics, the researchers found that use of these calcium-channel blockers was associated with a 33 percent greater risk of a major adverse kidney event, reported as a hazard ratio of 1.33 with a 95 percent confidence interval of 1.03 to 1.73. The researchers defined those events specifically as either a major loss of filtering capacity, meaning a decline of 40 percent or more in estimated glomerular filtration rate, the standard measure of kidney function, or progression to end-stage kidney disease requiring dialysis or a transplant. The lower bound of the confidence interval sitting just above 1.0 indicates the association was statistically significant but not far from the threshold of uncertainty.

How the drugs may strain the kidney’s filters

The researchers offered a physiological explanation for why the association might exist. In diabetic kidney disease, the tiny filtering structures of the kidney are already coping with elevated pressure and hyperfiltration, a state in which they are placed under excessive strain. Dihydropyridine calcium-channel blockers may relax the vessels carrying blood into these filtering units more strongly than they relax the vessels carrying blood away. That imbalance could raise pressure inside the filters and, over time, potentially contribute to further damage. The condition itself develops as prolonged high blood sugar injures the small blood vessels of the kidney, which is why blood-pressure control is central to slowing its progression, as explained by the U.S. National Institute of Diabetes and Digestive and Kidney Diseases in its overview of diabetic kidney disease.

Why this is an association, not proof of harm

An important limitation frames the entire finding. Because the study was observational, drawing on records of how patients were actually treated rather than randomly assigning them to different drugs, it cannot demonstrate that the calcium-channel blockers directly caused the poorer kidney outcomes. Patients prescribed these medications may differ in ways that independently affect kidney risk, and such differences are difficult to fully account for even with statistical adjustment. The lead author noted that the team had initially expected the kidney-protective effects of SGLT2 inhibitors to offset any potential harm, yet the increased risk appeared to persist even in that group. The researchers called for prospective studies and randomized controlled trials to confirm the observation and to better define the safest blood-pressure strategies.

What it could mean for diabetic kidney disease care

For now, the results are best understood as a caution flag rather than a directive. The findings were presented at a scientific congress, a stage at which research is shared with the field but may not yet have completed full peer review and publication. Patients taking these medications are generally advised not to stop prescribed drugs on their own, since abruptly halting blood-pressure treatment carries its own risks, and any changes are decisions for a clinician who knows the full picture. What the study does add is a reason for physicians to weigh the choice of second-line blood-pressure therapy more carefully in diabetic kidney disease, particularly as the evidence base around kidney-protective treatment continues to evolve.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview